Tempus AI extended its data license agreement with Recursion Pharmaceuticals through November 2029. The amended contract guarantees $42 million in committed payments over the next three years. This agreement replaces previous discretionary fees to support foundation models for precision medicine. The partnership originally launched in 2023.
Goldman Sachs initiated coverage of Tempus AI with a Neutral rating. The firm established a $75 price target for the stock. Analysts cited strong diagnostics growth alongside risks regarding mid-term data contract renewals. The report also highlighted Tempus AI’s development of a large-scale whole genome research platform.